Galmed Pharma (NASDAQ: GLMD) reported Q2 EPS of ($0.22), $0.05 better than the analyst estimate of ($0.27).

Cash and cash equivalents and marketable securities totaled $9.1 million as of June 30, 2017, compared to $15.5 million at December 31, 2016. The decrease in cash resulted primarily from the costs of our ongoing clinical studies and operational activities. Galmed continues to believe that its cash balance will be sufficient to maintain its current operations through the first half of 2018, and allow the Company to complete the ARREST study as scheduled.

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.